Alkalizing agents for blood purification
An alkalinizing agent-based composition addresses the challenge of high uremic substance levels in CKD by promoting excretion and reducing blood concentrations, thereby improving renal function and reducing cardiovascular risks.
Patent Information
- Application Number
- JP2022180936
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-04-18
- Filing Date
- 2022-11-11
- Publication Date
- 2024-11-06
- Estimated Expiration
- 2037-04-24
AI Technical Summary
Current treatments for chronic kidney disease (CKD) are insufficient in reducing the concentration of uremic substances like indoxyl sulfate, which contribute to renal damage and cardiovascular complications, and there is a need for agents that can delay the progression to end-stage kidney disease and improve metabolic acidosis.
A pharmaceutical composition containing alkalinizing agents such as potassium citrate and sodium citrate is administered to increase the pH of bodily fluids, promoting the excretion of uremic substances into the urine and reducing their concentration in the blood, thereby mitigating renal and cardiovascular issues.
The composition effectively lowers blood concentrations of indoxyl sulfate and other uremic toxins, improving renal tubular function, delaying dialysis, and reducing cardiovascular risks in CKD patients.
Smart Images

Figure 0007578243000001 
Figure 0007578243000002 
Figure 0007578243000003
Abstract
Description
[Technical field]
[0001] The present invention relates to blood purification with an alkalizing agent. [Background technology]
[0002] The number of patients with end-stage kidney disease (ESKD) who require dialysis or transplants is increasing worldwide. The number is also on the rise in Japan, where the number of dialysis patients reached 320,000 at the end of 2014. Chronic kidney disease (CKD) is recognized as a precursor to ESKD. CKD is a concept that encompasses all chronic kidney diseases, regardless of the underlying disease, and includes all pathological conditions in which there is a decrease in renal function represented by glomerular filtration rate (GFR) or findings suggesting kidney damage persist chronically (for more than 3 months). CKD is not only a risk factor for progression to ESKD, but also a strong risk factor for developing cardiovascular disease (CVD), etc., so it is very important to detect CKD early and provide appropriate treatment. Many CKD treatments have been established so far, but they are still insufficient, and further development of renal protective agents is required.
[0003] In CKD, various uremic substances accumulate in the body due to a decrease in renal clearance. Among them, the blood concentration of indoxyl sulfate, which is a terminal metabolic product of tryptophan, increases with the progression of CKD, and high concentrations (100 μM to 1 mM) of indoxyl sulfate accumulate in the blood. Indoxyl sulfate is known to be deeply involved in CKD complications such as the progression of renal damage due to renal fibrosis and CVD due to vascular calcification, and it has been reported that the concentration of indoxyl sulfate in serum correlates with the mortality rate and incidence rate of cardiovascular events in dialysis patients (Non-Patent Document 1). It is believed that the progression to ESKD and the onset of CVD associated with renal failure can be suppressed by reducing the concentration of indoxyl sulfate in the blood of CKD patients. In fact, a spherical adsorbent carbon preparation (Kremezin (registered trademark)) that adsorbs indole, a precursor of indoxyl sulfate, in the intestinal tract and reduces the concentration of indoxyl sulfate in the blood delays the introduction of dialysis in CKD patients and improves arteriosclerosis (Non-Patent Document 2).
[0004] On the other hand, in advanced CKD patients, the blood bicarbonate ion (HCO3 - ) concentration decreases, leading to the onset of metabolic acidosis, and therefore alkaline agents such as sodium bicarbonate and citric acid preparations are administered. It has been reported that administration of sodium bicarbonate, an alkaline agent, inhibits the progression of CKD (Non-Patent Document 3). It has also been reported that oral administration of sodium bicarbonate inhibits renal tubule cell injury caused by acidic urine in a nephrotic animal model (Non-Patent Document 4). However, there have been no reports on the inhibition of progression of renal damage by administering an alkalizing agent to early stage CKD patients, nor on the reduction of blood concentrations of uremic substances. [Prior art documents] [Non-patent literature]
[0005] [Non-Patent Document 1] Barreto, FC, et al.: Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin. J. Am. Soc. Nephrol., 4: 1551-1558, 2009. [Non-Patent Document 2] Nakamura T., et al.: Oral ADSORBENT AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure. Kidney Blood Press Res, 27: 121-6, 2004. [Non-Patent Document 3] Brito-Ashurst, ID, et al.: Bicarbonate supplementation slows progression of CKD and improves nutritional status. J. Am. Soc. Nephrol., 20: 2075-2084, 2009. [Non-Patent Document 4] Souma T., et al.: Luminal alkalinization attenuates proteinuria-induced oxidative damage in proximal tubular cells. J. Am. Soc. Nephrol., 22: 635-648, 2011. Summary of the Invention [Problem to be solved by the invention]
[0006] One object of the present invention is to provide a medicine useful for blood purification in patients with kidney disease. Another object of the present invention is to provide a medicine useful for inhibiting the progression of chronic kidney disease (aggravation of chronic kidney disease), treating and preventing uremic symptoms, and delaying the initiation of dialysis. Another object of the present invention is to provide a medicine useful for inhibiting the progression of acute kidney disease to chronic kidney disease. Another object of the present invention is to provide a food for promoting the excretion of uremic substances from the body. Another object of the present invention is to provide a method for determining inhibition of the progression of chronic kidney disease, and a method for determining a reduction in the concentration of uremic substances in the blood and / or promotion of excretion of uremic substances in the urine. [Means for solving the problem]
[0007] Means for Solving the Problems The present inventors have conducted intensive research to achieve the above object and have found that drugs that alkalize body fluids are useful for promoting the excretion of uremic substances from the bodies of patients with kidney disease (e.g., promoting the excretion of uremic substances into urine), thereby completing the present invention.
[0008] In one aspect, the present invention provides a pharmaceutical composition for promoting excretion of uremic substances from the body, which comprises an alkalizing agent.
[0009] In one aspect, the present invention provides a pharmaceutical composition for reducing the blood concentration of a uremic substance, which comprises an alkalizing agent.
[0010] In one aspect, the present invention provides a pharmaceutical composition for promoting urinary excretion of uremic substances, which comprises an alkalizing agent.
[0011] In one aspect, the present invention provides a pharmaceutical composition for ameliorating uremic symptoms in chronic kidney disease, comprising an alkalizing agent.
[0012] In one aspect, the present invention provides a pharmaceutical composition for delaying the initiation of dialysis in chronic kidney disease, comprising an alkalizing agent.
[0013] In one aspect, the present invention provides a pharmaceutical composition for treating or preventing cardiovascular disease associated with chronic kidney disease, comprising an alkalizing agent.
[0014] In one aspect, the present invention provides a pharmaceutical composition for inhibiting progression from acute kidney disease to chronic kidney disease, comprising an alkalizing agent.
[0015] In one aspect, the present invention provides a food composition for promoting excretion of uremic substances from the body, which contains an alkalizing agent.
[0016] In one aspect, the present invention provides a method for determining inhibition of progression of chronic kidney disease.
[0017] In one aspect, the present invention provides a method for determining a reduction in the concentration of a uremic toxin in human blood and / or promotion of excretion of a uremic toxin in urine. Effect of the Invention
[0018] The pharmaceutical composition etc. provided by the present invention allows uremic substances to be excreted from the body in mammals. The method provided by the present invention allows a preliminary judgment as to whether uremic substances are being excreted from the body and / or whether the progression of chronic kidney disease has been inhibited. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0019] 1. Pharmaceutical Compositions In one embodiment, the pharmaceutical composition provided herein comprises an alkalizing agent. An alkalizing agent is a substance that reduces the amount of HCO3 in the body fluids of a mammal (especially a human), such as blood or urine. -An agent capable of increasing concentration or pH. Examples of alkalizing agents include citric acid, its hydrates or mixtures thereof, and sodium bicarbonate (sodium bicarbonate). Examples of citric acid include alkali metal citrates. Examples of alkali metal citrates include potassium citrate and sodium citrate, which may be hydrated, such as the stable potassium citrate monohydrate (C6H5K3O7·H2O) and sodium citrate dihydrate (C6H5Na3O7·2H2O), respectively. Examples of preferred alkalizing agents include sodium citrate, potassium citrate or its hydrate or a mixture thereof, and may be, for example, a mixture of potassium citrate monohydrate (C6H5K3O7·H2O) and sodium citrate dihydrate (C6H5Na3O7·2H2O). The mixing ratio of potassium citrate monohydrate (C6H5K3O7·H2O) and sodium citrate dihydrate (C6H5Na3O7·2H2O) can be appropriately set by those skilled in the art, and for example, the molar ratio of potassium citrate monohydrate and sodium citrate dihydrate can be 1 part potassium citrate monohydrate to 0.01 to 100 parts sodium citrate dihydrate. The mixing ratio may be about 1:1 in molar ratio. Other examples of preferred alkalizing agents include sodium citrate or a hydrate thereof, such as sodium citrate dihydrate (C6H5Na3O7·2H2O). Other examples of preferred alkalizing agents include potassium citrate or a hydrate thereof, such as potassium citrate monohydrate (C6H5K3O7·H2O).
[0020] As used herein, uremic substances refer to substances (waste products, toxins, etc.) excreted by normal kidneys, which increase (accumulate) in the blood and cause uremic symptoms or diseases when the excretory function is reduced due to some cause such as reduced renal function. Examples of uremic substances include indoxyl sulfate, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid, and argininosuccinic acid. Of these, indoxyl sulfate is produced in the liver by oxidation and sulfate conjugation of indole produced by intestinal bacteria from tryptophan derived from dietary protein. Most indoxyl sulfate exists in the blood bound to albumin and is not metabolized, and is excreted in the urine by the kidneys in healthy people, but in patients with kidney disease, it remains accumulated in high concentrations in the blood due to reduced renal function. Indoxyl sulfate, a uremic substance, not only induces uremia in patients with kidney disease, but also accumulates in renal tubular cells, causing renal tubular cell damage and forcing patients with chronic kidney disease to undergo dialysis. Therefore, by lowering the indoxyl sulfate concentration in blood, uremic symptoms of kidney disease patients are improved, and uremia can be treated and / or prevented.In addition, by lowering the indoxyl sulfate concentration in blood, renal tubule cell damage can be suppressed, renal tubule function (e.g., reabsorption of glucose, amino acids, etc.) can be maintained, and the introduction of dialysis in chronic kidney disease patients can be delayed.In one embodiment, the chronic kidney disease patient has progressive chronic kidney disease.
[0021] In addition, indoxyl sulfate, a uremic substance, induces myocardial fibrosis, arteriosclerosis, proliferation of vascular smooth muscle cells, vascular endothelial cell damage, thickening of the arterial wall, calcification of the aorta, and other conditions, leading to cardiovascular diseases (e.g., heart failure, myocardial infarction, stroke, etc.), which are complications in patients with chronic kidney disease. Therefore, by lowering the blood concentration of indoxyl sulfate, it is possible to suppress myocardial fibrosis, arteriosclerosis, proliferation of vascular smooth muscle cells, vascular endothelial cell damage, thickening of the arterial wall, calcification of the aorta, etc., and to treat and / or prevent cardiovascular disease, which is one of the complications of chronic kidney disease patients.
[0022] The pharmaceutical composition provided by the present invention is capable of lowering the concentration of uremic substances in the blood (e.g., indoxyl sulfate, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid and / or argininosuccinic acid, preferably indoxyl sulfate and phenylacetyl-L-glutamine, more preferably indoxyl sulfate). In addition, the pharmaceutical composition provided by the present invention is capable of promoting excretion of uremic substances (e.g., indoxyl sulfate, p-cresyl sulfate, phenylacetyl L-glutamine, hippuric acid and / or argininosuccinic acid, preferably indoxyl sulfate, p-cresyl sulfate and / or phenylacetyl L-glutamine, more preferably indoxyl sulfate and phenylacetyl L-glutamine, even more preferably indoxyl sulfate) into the urine. Due to these characteristics of the pharmaceutical composition provided by the present invention, the pharmaceutical composition provided by the present invention can be used not only as a pharmaceutical composition for reducing the blood concentration of uremic substances and / or a pharmaceutical composition for promoting urinary excretion of uremic substances, but also as any one of a pharmaceutical composition for improving uremic symptoms in patients with kidney disease, a pharmaceutical composition for treating and / or preventing uremia in patients with kidney disease, a pharmaceutical composition for inhibiting tubular (e.g., proximal tubule) cell damage in patients with kidney disease, a pharmaceutical composition for maintaining tubular function (e.g., proximal tubule) in patients with kidney disease, a pharmaceutical composition for inhibiting the progression of chronic kidney disease, and a pharmaceutical composition for delaying the initiation of dialysis in patients with chronic kidney disease. Furthermore, due to the characteristics of the pharmaceutical composition provided by the present invention as described above, the pharmaceutical composition provided by the present invention can also be used as any one of a pharmaceutical composition for suppressing myocardial fibrosis in a patient with kidney disease, a pharmaceutical composition for suppressing arteriosclerosis in a patient with kidney disease, a pharmaceutical composition for suppressing the proliferation of vascular smooth muscle cells in a patient with kidney disease, a pharmaceutical composition for suppressing vascular endothelial cell damage in a patient with kidney disease, a pharmaceutical composition for suppressing arterial wall thickening in a patient with kidney disease, a pharmaceutical composition for suppressing aortic calcification in a patient with kidney disease, and a pharmaceutical composition for treating and / or preventing cardiovascular diseases associated with chronic kidney disease.
[0023] Furthermore, it has been reported that when a drug that reduces the blood concentration of indoxyl sulfate was administered to patients with non-diabetic chronic kidney disease, the pulse wave velocity and carotid intima-media thickness, which are indicators of arteriosclerosis, were significantly improved compared to before administration (Nakamura T., et al.: Oral ADSORBENT AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure. Kidney Blood Press Res, 27: 121-6, 2004.), so the pharmaceutical composition provided by the present invention that reduces the blood concentration of indoxyl sulfate can be used as a pharmaceutical composition for improving arteriosclerosis or a pharmaceutical composition for improving thickening of the arterial (e.g., carotid) wall in patients with kidney disease (preferably patients with chronic kidney disease, more preferably patients with non-diabetic chronic kidney disease).
[0024] In addition, it has been reported that drugs that reduce the blood concentration of indoxyl sulfate suppress acute kidney injury induced by cisplatin (Morisaki T., et. Al.,: Regulation of renal organic ion transporters in cisplatin-induced acute kidney injury and uremia in rats. Pharm. Res., 25(11): 2526-33, 2008). Therefore, the pharmaceutical composition provided by the present invention that reduces the blood concentration of indoxyl sulfate can be used as a pharmaceutical composition for treating acute kidney disease or a pharmaceutical composition for suppressing the progression of acute kidney disease to chronic kidney disease.
[0025] In addition, it has been reported that p-cresyl sulfate, a uremic substance, is a causative agent of vascular endothelial damage (Meijers BK, et. Al.,: The uremic retention solute p-cresyl sulfate and markers of endothelial damage., Am. J. Kidney Dis., 54: 891-901, 2009). Therefore, the pharmaceutical composition provided by the present invention, which promotes urinary excretion of p-cresyl sulfate, can be used as a pharmaceutical composition for suppressing vascular endothelial damage in patients with kidney disease (preferably patients with chronic kidney disease). In addition, it has been reported that the uremic substance phenylacetyl-L-glutamine increases the risk of developing cardiovascular disease in patients with chronic kidney disease. Therefore, the pharmaceutical composition provided by the present invention, which promotes urinary excretion of phenylacetyl-L-glutamine, can be used as a pharmaceutical composition for treating and / or preventing cardiovascular diseases in patients with chronic kidney disease. The pharmaceutical composition provided by the present invention promotes the urinary excretion of uremic substances such as indoxyl sulfate, p-cresyl sulfate, hippuric acid, argininosuccinic acid, phenylacetyl L-glutamine, etc., and therefore the pharmaceutical composition provided by the present invention can be used as a pharmaceutical composition for promoting the urinary excretion of indoxyl sulfate, p-cresyl sulfate, hippuric acid, argininosuccinic acid and / or phenylacetyl L-glutamine in patients with kidney disease (preferably patients with chronic kidney disease) (e.g., a composition for promoting the urinary excretion of indoxyl sulfate and phenylacetyl L-glutamine, a composition for promoting the urinary excretion of indoxyl sulfate, a composition for promoting the urinary excretion of phenylacetyl L-glutamine).
[0026] The pharmaceutical compositions provided by the present invention may be administered to humans or other mammals orally or parenterally. Examples of parenteral administration include intravenous, subcutaneous, intramuscular, intraarticular, transmucosal, transdermal, nasal, rectal, intrathecal, intraperitoneal, and topical administration. The pharmaceutical composition provided by the present invention may be prepared by mixing the alkalizing agent as it is or with a pharma- ceutically acceptable carrier, for example, an excipient (e.g., lactose, D-mannitol, crystalline cellulose, glucose), a binder (e.g., hydroxypropylcellulose (HPC), gelatin, polyvinylpyrrolidone (PVP)), a lubricant (e.g., magnesium stearate, talc), a disintegrant (e.g., starch, carboxymethylcellulose calcium (CMC-Ca)), a diluent (e.g., water for injection, physiological saline), and, if necessary, other additives (e.g., pH adjusters, surfactants, solubilizing agents, preservatives, emulsifiers, isotonicity agents, stabilizers), and may be in the form of tablets, capsules, suspensions, injections, suppositories, and the like. For example, to prepare a tablet, the alkalizing agent may be mixed with an excipient (e.g., lactose, D-mannitol, crystalline cellulose, glucose), a disintegrant (e.g., starch, carboxymethylcellulose calcium (CMC-Ca)), a binder (e.g., hydroxypropylcellulose (HPC), gelatin, polyvinylpyrrolidone (PVP)), a lubricant (e.g., magnesium stearate, talc), etc. to form a tablet.
[0027] The amount of the alkalizing agent in the pharmaceutical composition provided by the present invention may be appropriately set. For example, the dosage of the alkalizing agent may be set so that the administration to a human improves acidic urine in gout or hyperuricemia, or the dosage may be set so that acidosis is improved. The dosage of the alkalizing agent that improves acidic urine in gout or hyperuricemia when administered to a human may be, for example, a dosage that adjusts the pH of the human urine (e.g., early morning urine) to pH 6.2 to 6.8 or pH 6.5 to 6.8 when the alkalizing agent is administered. In one embodiment, the pharmaceutical composition provided by the present invention is a tablet, and each tablet may contain 10 mg to 1 g, preferably 100 mg to 500 mg, and more preferably 400 mg to 500 mg of potassium citrate monohydrate or sodium citrate dihydrate as an alkalizing agent. In one embodiment, the pharmaceutical composition provided by the present invention is a tablet, and each tablet may contain 10 mg to 300 mg of potassium citrate monohydrate and sodium citrate dihydrate, for a total of 20 mg to 600 mg, preferably 150 to 250 mg of each and 400 to 500 mg of total, and more preferably 190 to 240 mg of each and 400 to 450 mg of total. In another embodiment, the pharmaceutical composition provided by the present invention is a tablet, and each tablet may contain 10 mg to 1 g, preferably 100 mg to 500 mg, of sodium bicarbonate as an alkalizing agent. Furthermore, as one embodiment, the pharmaceutical composition provided by the present invention is a tablet, which contains 231.5 mg of potassium citrate monohydrate and 195.0 mg of sodium citrate dihydrate as alkalizing agents, and may contain anhydrous citric acid, crystalline cellulose, partially pregelatinized starch, hydroxypropyl cellulose, magnesium stearate, hypromellose, macrogol 6000, titanium oxide and carnauba wax as excipients.
[0028] The dosage of the alkalizing agent is determined appropriately depending on the type of alkalizing agent, the method of administration, and the age, weight, sex, symptoms, and sensitivity to the drug of the subject, but the dosage may be adjusted depending on the degree of improvement of the symptoms. In one embodiment, when a mixture of potassium citrate monohydrate and sodium citrate dihydrate is orally administered to a human as an alkalizing agent, potassium citrate monohydrate and sodium citrate dihydrate may be administered at 0.1 to 5 g / day each for a total of 0.2 to 10 g / day, 0.1 to 3 g / day each for a total of 0.2 to 6 g / day, 0.5 to 3 g / day each for a total of 1 to 6 g / day, preferably 0.5 to 1.5 g / day each for a total of 1 to 3 g / day, 1 to 1.5 g / day each for a total of 2 to 3 g / day, or 0.5 to 1 g / day each for a total of 1 to 2 g / day, and may be administered 1 to 5 times a day, preferably 3 times a day. In one embodiment, when potassium citrate monohydrate or sodium citrate dihydrate is orally administered to a human as an alkalizing agent, 1 to 10 g / day, 1 to 6 g / day, 2 to 5.5 g / day, 1 to 3 g / day, 2 to 3 g / day, or 1 to 1.5 g / day may be administered, and may be administered 1 to 5 times a day, preferably 3 times a day. In one embodiment, when sodium bicarbonate is orally administered to a human as an alkalizing agent, it may be administered at a dose of 1 to 6 g / day, preferably 3 to 5 g / day, in 1 to 5 divided doses per day, preferably 3 times per day.
[0029] In one embodiment, the alkalinizing agent may be administered chronically, for example, for 1 week or more, 2 weeks or more, 3 weeks or more, 6 weeks or more, 8 weeks or more, 10 weeks or more, 12 weeks or more, 24 weeks or more, 6 weeks or more but not more than 24 weeks, 12 weeks or more but not more than 24 weeks, or 12 weeks or more but not more than 30 weeks. In one embodiment, when a mixture of potassium citrate monohydrate and sodium citrate dihydrate is orally administered to humans as an alkalizing agent, the blood concentration of indoxyl sulfate begins to decrease between 6 and 12 weeks after administration compared to before administration, and its excretion in urine begins to increase between 6 and 12 weeks after administration compared to before administration.Also, in this embodiment, the excretion of p-cresyl sulfate in urine begins to increase between 6 and 12 weeks after administration compared to before administration, the blood concentration of hippuric acid begins to decrease between 12 and 24 weeks after administration compared to before administration, and the excretion of hippuric acid in urine begins to increase between 0 and 6 weeks after administration compared to before administration.Furthermore, in this embodiment, the excretion of argininosuccinic acid in urine begins to increase between 6 and 12 weeks after administration compared to before administration, and the excretion of phenylacetyl-L-glutamine in urine begins to increase between 6 and 12 weeks after administration compared to before administration. Considering the above embodiments, when a mixture of potassium citrate monohydrate and sodium citrate dihydrate is orally administered to a human, it may be administered for, for example, 6 weeks or more, preferably 12 weeks or more, and more preferably 24 weeks or more.
[0030] In one embodiment, the pharmaceutical compositions provided herein are administered to a human suffering from kidney disease, which includes acute kidney disease and chronic kidney disease, unless otherwise specified. Examples of acute kidney disease include acute kidney disease caused by drugs (e.g., nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, aminoglycoside antibiotics, new quinolone antibacterial agents, iodine contrast agents, platinum preparations such as cisplatin) and acute kidney disease caused by renal ischemia. Chronic kidney disease (CKD) is a concept that encompasses all chronic kidney diseases, regardless of the underlying disease, and includes all pathological conditions in which there is a decline in renal function, as measured by glomerular filtration rate (GFR), or signs suggesting kidney damage persist chronically (for three months or more).
[0031] According to the CKD Clinical Practice Guide 2012 (Journal of the Japanese Society of Nephrology 2012), the severity of chronic kidney disease is evaluated by classification based on cause (Cause: C), renal function (GFR: G), and proteinuria (albuminuria: A). The GFR classification is as follows: G1: Normal or high GFR (≥ 90 mL / min / 1.73 m 2 ) G2: Normal or mildly decreased GFR (60-89 mL / min / 1.73 m 2 ) G3a: Mild to moderate decrease in GFR (45 to 59 mL / min / 1.73 m 2 ) G3b: Moderate to severe decline in GFR (30 to 44 mL / min / 1.73 m 2 ) G4: Severely decreased GFR (15-29 mL / min / 1.73 m 2 ) G5: End-stage renal disease (ESKD) (<15 mL / min / 1.73 m 2 ) When the primary disease is diabetes, proteinuria (albuminuria: A) is classified as follows using the urinary albumin / creatinine (Cr) ratio: A1: Normal (less than 30 mg / gCr) A2: Microalbuminuria (30-299 mg / gCr) A3: Macroalbuminuria (300 mg / gCr or more) In addition, classification of proteinuria (albuminuria: A) when the primary disease is hypertension, nephritis, polycystic kidney disease, kidney transplant, or other diseases other than diabetes, is performed using the urinary protein / creatinine (Cr) ratio as follows: A1: Normal (less than 0.15 g / gCr) A2: Mild proteinuria (0.15~0.49 g / gCr) A3: Severe proteinuria (0.50 g / gCr or more) According to the CKD Treatment Guide 2012 (Journal of the Japanese Society of Nephrology 2012), the severity classification of chronic kidney disease (CKD) is expressed using the above C, G, and A, for example, diabetes G2A3, chronic nephritis G3bA1, etc. However, taking into consideration that the severity of chronic kidney disease has traditionally been expressed only in stages classified by GFR, it is now possible to continue to express the severity of chronic kidney disease in stages, G1, G2, G3a, G3b, G4, and G5, as in the past.
[0032] In one embodiment, the pharmaceutical compositions provided herein are administered to patients with less severe, early stage chronic kidney disease. In one embodiment, the pharmaceutical composition provided by the present invention is administered to a patient with chronic kidney disease at stage G3b or below, preferably at stage G2 or below. In one embodiment, the pharmaceutical composition provided by the present invention is administered to a chronic kidney disease patient whose stage is G3b or lower and whose urinary protein excretion is less than 3.5 g / gCr, preferably to a chronic kidney disease patient whose stage is G2 and whose urinary protein excretion is less than 3.5 g / gCr. In one embodiment, the pharmaceutical compositions provided herein are administered to patients with progressing chronic kidney disease.
[0033] In one embodiment, the pharmaceutical composition provided by the present invention is administered to a patient undergoing treatment in accordance with the CKD Medical Care Guide, for example, to a patient undergoing blood pressure control (administration of RA system suppressants such as ARBs and ACE inhibitors, diuretics, Ca antagonists, etc.), proteinuria control (administration of RA system suppressants, etc.), blood glucose control (administration of α-glucosidase inhibitors, etc.), lipid control (administration of statins, fibrates, etc.), anemia control (administration of erythropoietin, etc.), and / or bone and mineral control (administration of bisphosphonates, etc.) in accordance with the CKD Medical Care Guide.
[0034] In one embodiment, the pharmaceutical composition provided by the present invention is administered to a patient with less severe, early stage chronic kidney disease (e.g., a patient with chronic kidney disease at stage G3b or below, preferably at stage G2) to reduce the concentration of uremic substances (e.g., indoxyl sulfate and / or phenylacetyl-L-glutamine) in the patient's blood and promote the excretion of uremic substances (e.g., indoxyl sulfate, p-cresyl sulfate, hippuric acid, argininosuccinic acid and / or phenylacetyl-L-glutamine) from the body (e.g., into the urine). In this embodiment, the pharmaceutical composition provided by the present invention may be a pharmaceutical composition for improving uremic symptoms, a pharmaceutical composition for treating or preventing uremia, a pharmaceutical composition for suppressing damage to renal tubule (e.g., proximal tubule) cells, a pharmaceutical composition for maintaining the function of renal tubule (e.g., proximal tubule) cells, a pharmaceutical composition for suppressing the progression of chronic kidney disease, a pharmaceutical composition for delaying the initiation of dialysis, a pharmaceutical composition for suppressing myocardial fibrosis, a pharmaceutical composition for suppressing arteriosclerosis, a pharmaceutical composition for improving arteriosclerosis, a pharmaceutical composition for suppressing the proliferation of vascular smooth muscle cells, a pharmaceutical composition for suppressing damage to vascular endothelial cells, a pharmaceutical composition for suppressing arterial wall thickening, a pharmaceutical composition for improving arterial wall thickening, a pharmaceutical composition for suppressing calcification of the aorta, or a pharmaceutical composition for treating or preventing a complication of cardiovascular disease (e.g., heart failure, myocardial infarction, stroke, etc.). In one embodiment, the pharmaceutical composition provided by the present invention is administered to a patient with chronic kidney disease of moderate or greater severity (e.g., a patient with chronic kidney disease at stage G3b or greater, preferably at stage G4 or greater) to reduce the concentration of uremic substances (e.g., indoxyl sulfate and / or phenylacetyl-L-glutamine) in the patient's blood and promote the excretion of uremic substances (e.g., indoxyl sulfate, p-cresyl sulfate, hippuric acid, argininosuccinic acid and / or phenylacetyl-L-glutamine) from the body (e.g., into the urine). In this embodiment, the pharmaceutical composition provided by the present invention may be a pharmaceutical composition for improving uremic symptoms, a pharmaceutical composition for treating or preventing uremia, a pharmaceutical composition for suppressing renal tubular (e.g., proximal tubular) cell damage, a pharmaceutical composition for maintaining renal tubular (e.g., proximal tubular) cell function, a pharmaceutical composition for suppressing the progression of chronic kidney disease, a pharmaceutical composition for delaying the initiation of dialysis, a pharmaceutical composition for suppressing myocardial fibrosis, a pharmaceutical composition for suppressing arteriosclerosis, a pharmaceutical composition for improving arteriosclerosis, a pharmaceutical composition for suppressing the proliferation of vascular smooth muscle cells, a pharmaceutical composition for suppressing vascular endothelial cell damage, a pharmaceutical composition for suppressing arterial wall thickening, a pharmaceutical composition for improving arterial wall thickening, a pharmaceutical composition for suppressing aortic calcification, or a pharmaceutical composition for treating or preventing a complication of cardiovascular disease (e.g., heart failure, myocardial infarction, stroke, etc.).
[0035] Examples of other embodiments of the present invention include the following. a) a method of reducing the blood concentration of a uremic substance in a mammalian subject (e.g., a human), comprising administering to a subject in need thereof an effective amount of an alkalizing agent; b) a method for enhancing the excretion of uremic substances from the body (e.g., in the urine) in a mammalian subject (e.g., a human), comprising administering to a subject in need thereof an effective amount of an alkalizing agent; c) a method for ameliorating uremic symptoms in a mammalian subject (e.g., a human), comprising administering to a subject in need of ameliorating uremic symptoms an effective amount of an alkalizing agent, wherein the subject is suffering from kidney disease; d) a method for the treatment or prevention of uremia in a mammalian subject (e.g., a human), comprising administering to a subject in need of such treatment or prevention an effective amount of an alkalinizing agent, wherein the subject is suffering from kidney disease; e) a method of inhibiting renal tubular (e.g., proximal tubule) cell damage in a mammalian subject (e.g., a human), the method comprising administering to a subject in need thereof an effective amount of an alkalinizing agent, the subject suffering from a kidney disease; f) a method of maintaining renal tubular (e.g. proximal tubule) cell function in a mammalian subject (e.g., a human), comprising administering to a subject in need of maintaining renal tubular (e.g., proximal tubule) cell function an effective amount of an alkalinizing agent, the subject suffering from kidney disease; g) a method of inhibiting the progression of chronic kidney disease in a mammalian subject (e.g., a human), comprising administering to a subject in need thereof an effective amount of an alkalizing agent; h) a method of delaying the onset of dialysis in a mammalian subject (e.g., a human), comprising administering to a subject in need of delayed onset of dialysis an effective amount of an alkalinizing agent, wherein the subject suffers from chronic kidney disease; i) a method of inhibiting myocardial fibrosis in a mammalian subject (e.g., a human), comprising administering to a subject in need thereof an effective amount of an alkalizing agent, wherein the subject is suffering from a kidney disease; j) a method of inhibiting arteriosclerosis in a mammalian subject (e.g., a human), comprising administering to a subject in need of inhibiting arteriosclerosis an effective amount of an alkalizing agent, wherein the subject is suffering from kidney disease; k) a method of inhibiting vascular smooth muscle cell proliferation in a mammalian subject (e.g., a human), comprising administering to a subject in need of inhibiting vascular smooth muscle cell proliferation an effective amount of an alkalizing agent, wherein the subject is suffering from kidney disease; l) A method for inhibiting vascular endothelial cell damage in a mammalian subject (e.g., a human), comprising administering to a subject in need of inhibiting vascular endothelial cell damage an effective amount of an alkalizing agent, wherein the subject suffers from kidney disease; m) a method for inhibiting thickening of an arterial wall in a mammalian subject (e.g., a human), comprising administering to a subject in need thereof an effective amount of an alkalizing agent, the subject suffering from kidney disease; n) a method for inhibiting aortic calcification in a mammalian subject (e.g., a human), comprising administering to a subject in need thereof an effective amount of an alkalinizing agent, the subject suffering from kidney disease; o) a method for treating or preventing cardiovascular disease in a mammalian subject (e.g., a human), comprising administering to a subject in need of such treatment or prevention an effective amount of an alkalizing agent, wherein the subject is suffering from kidney disease; p) a method for ameliorating arteriosclerosis in a mammalian subject (e.g., a human), comprising administering to a subject in need of amelioration of arteriosclerosis an effective amount of an alkalizing agent, the subject suffering from kidney disease; q) a method for improving arterial wall thickening in a mammalian subject (e.g., a human), comprising administering to a subject in need of improving arterial wall thickening an effective amount of an alkalizing agent, the subject suffering from kidney disease; r) a method for treating acute kidney disease in a mammalian subject (e.g., a human), comprising administering to a subject in need of treatment for acute kidney disease an effective amount of an alkalinizing agent; s) a method for inhibiting the progression of acute kidney disease to chronic kidney disease in a mammalian subject (e.g., a human), the method comprising administering to a subject in need thereof an effective amount of an alkalizing agent; aa) alkalizing agents for use as agents for reducing the blood concentration of uremic substances; bb) alkalizing agents for use as agents promoting the excretion of uremic substances from the body (e.g. in the urine); cc) an alkalizing agent for use as an agent for improving uraemic symptoms in patients with kidney disease; dd) An alkalizing agent for use as an agent for the treatment or prevention of uremia in patients with kidney disease; ee) an alkalinizing agent for use as an inhibitor of renal tubular (e.g. proximal tubule) cell damage in patients with kidney disease; ff) an alkalinizing agent for use as an agent for maintaining renal tubular (e.g. proximal tubule) cell function in patients with kidney disease; gg) an alkalizing agent for use as an inhibitor of the progression of chronic kidney disease; hh) an alkalinizing agent for use as an agent for delaying the initiation of dialysis in patients with chronic kidney disease; ii) an alkalizing agent for use as an inhibitor of myocardial fibrosis in patients with kidney disease; jj) an alkalizing agent for use as an anti-arteriosclerosis agent in patients with kidney disease; kk) an alkalizing agent for use as an inhibitor of vascular smooth muscle cell proliferation in patients with kidney disease; ll) an alkalizing agent for use as an inhibitor of vascular endothelial cell damage in patients with kidney disease; mm) an alkalizing agent for use as an inhibitor of arterial wall thickening in patients with kidney disease; nn) an alkalizing agent for use as an inhibitor of aortic calcification in patients with renal disease; oo) an alkalizing agent for use as an agent for the treatment or prevention of cardiovascular disease in patients with renal disease; pp) an alkalizing agent for use as an agent for improving arteriosclerosis in patients with kidney disease; qq) an alkalizing agent for use as an agent for improving arterial wall thickening in patients with kidney disease; rr) an alkalizing agent, for use as a treatment for acute kidney disease; ss) an alkalinizing agent for use as an inhibitor of the progression of acute kidney disease to chronic kidney disease; aaa) alkalizing agents for use in reducing blood levels of uremic substances; bbb) Alkalizing agents for use in promoting the excretion of uremic substances in the urine; ccc) an alkalizing agent for use in improving uraemic symptoms in patients with kidney disease; ddd) An alkalizing agent for use in the treatment or prevention of uremia in patients with kidney disease; eee) alkalinizing agents for use in inhibiting tubular (e.g. proximal tubule) cell damage in patients with renal disease; fff) an alkalizing agent for use in maintaining renal tubular (e.g. proximal tubule) cell function in patients with kidney disease; ggg) an alkalizing agent for use in inhibiting the progression of chronic kidney disease; hhh) Alkalizing agents for use in delaying the initiation of dialysis in patients with chronic kidney disease; iii) an alkalizing agent for use in inhibiting myocardial fibrosis in patients with renal disease; jjj) an alkalizing agent for use in inhibiting arteriosclerosis in patients with renal disease; kkk) an alkalizing agent for use in inhibiting the proliferation of vascular smooth muscle cells in patients with renal disease; lll) Alkalizing agents for use in inhibiting vascular endothelial cell damage in patients with renal disease; mmm) an alkalizing agent for use in inhibiting thickening of the arterial wall in patients with kidney disease; nnn) an alkalizing agent for use in inhibiting aortic calcification in patients with renal disease; ooo) alkalizing agents for use in the treatment or prevention of cardiovascular disease in patients with renal disease; ppp) an alkalizing agent for use in ameliorating arteriosclerosis in patients with kidney disease; qqq)An alkalizing agent for use in improving arterial wall thickening in patients with kidney disease; rrr) an alkalizing agent, for use in the treatment of acute kidney disease; sss)An alkalinizing agent for use in inhibiting the progression of acute kidney disease to chronic kidney disease; aaaa) use of an alkalizing agent for producing a pharmaceutical composition for reducing the blood concentration of a uremic substance; bbbb) Use of an alkalizing agent for producing a pharmaceutical composition for promoting excretion of uremic substances from the body (e.g., into the urine); cccc) Use of an alkalizing agent for the manufacture of a pharmaceutical composition for improving uremic symptoms in patients with kidney disease; dddd) Use of an alkalizing agent for the manufacture of a pharmaceutical composition for the treatment or prevention of uremia in patients with kidney disease; eeee) Use of an alkalizing agent for producing a pharmaceutical composition for suppressing renal tubule (e.g. proximal tubule) cell damage in a patient with kidney disease; ffff) use of an alkalizing agent for the manufacture of a pharmaceutical composition for maintaining renal tubule (e.g. proximal tubule) cell function in a patient with kidney disease; gggg) Use of an alkalizing agent for producing a pharmaceutical composition for inhibiting the progression of chronic kidney disease; hhhh) Use of an alkalizing agent for the manufacture of a pharmaceutical composition for delaying the initiation of dialysis in patients with chronic kidney disease; iiii) Use of an alkalizing agent for producing a pharmaceutical composition for inhibiting myocardial fibrosis in a patient with kidney disease; jjjj) Use of an alkalizing agent for producing a pharmaceutical composition for inhibiting arteriosclerosis in a patient with kidney disease; kkkk) Use of an alkalizing agent for producing a pharmaceutical composition for inhibiting proliferation of vascular smooth muscle cells in patients with kidney disease; llll) Use of an alkalizing agent for producing a pharmaceutical composition for inhibiting vascular endothelial cell damage in patients with kidney disease; mmmm) Use of an alkalizing agent for producing a pharmaceutical composition for inhibiting arterial wall thickening in patients with kidney disease; nnnn) Use of an alkalizing agent for producing a pharmaceutical composition for inhibiting aortic calcification in patients with kidney disease; oooo) The use of an alkalizing agent for the preparation of a pharmaceutical composition for the treatment or prevention of cardiovascular diseases in patients with kidney disease; pppp) Use of an alkalizing agent for producing a pharmaceutical composition for improving arteriosclerosis in patients with kidney disease; qqqq) Use of an alkalizing agent for producing a pharmaceutical composition for improving arterial wall thickening in patients with kidney disease; rrrr) the use of an alkalizing agent for the preparation of a pharmaceutical composition for the treatment of acute kidney disease; and ssss) Use of an alkalizing agent for producing a pharmaceutical composition for inhibiting the progression of acute kidney disease to chronic kidney disease. In the above embodiments a) to ssss), the alkalizing agent may be a pharma- ceutically acceptable salt of citric acid, or a hydrate thereof, or a mixture thereof, or sodium bicarbonate. Examples of the pharma- ceutically acceptable salt of citric acid include alkali metal citrates, and examples of the alkali metal citrates include potassium citrate and sodium citrate, which may be hydrates such as stable potassium citrate monohydrate (C6H5K3O7·H2O) and sodium citrate dihydrate (C6H5Na3O7·2H2O), respectively. Examples of preferred alkalizing agents include sodium citrate, potassium citrate or its hydrate or a mixture thereof, and may be, for example, a mixture of potassium citrate monohydrate (C6H5K3O7·H2O) and sodium citrate dihydrate (C6H5Na3O7·2H2O). The mixing ratio of potassium citrate monohydrate (C6H5K3O7·H2O) and sodium citrate dihydrate (C6H5Na3O7·2H2O) can be appropriately set by those skilled in the art, and for example, the molar ratio of potassium citrate monohydrate and sodium citrate dihydrate can be 1 part potassium citrate monohydrate to 0.01 to 100 parts sodium citrate dihydrate. The mixing ratio may be about 1:1 in molar ratio. Other examples of preferred alkalizing agents include sodium citrate or a hydrate thereof, such as sodium citrate dihydrate (C6H5Na3O7·2H2O). Other examples of preferred alkalizing agents include potassium citrate or a hydrate thereof, such as potassium citrate monohydrate (C6H5K3O7·H2O). The amount of the alkalizing agent can be appropriately set. For example, when the alkalizing agent is selected from the group consisting of potassium citrate monohydrate, sodium citrate dihydrate, a mixture of potassium citrate monohydrate and sodium citrate dihydrate, and sodium bicarbonate, the amount may be 10 mg to 1 g, preferably 100 mg to 500 mg, and more preferably 400 mg to 500 mg. The dosage of the alkalizing agent may be an amount that improves acidic urine in gout or hyperuricemia when administered to a human, or an amount that improves acidosis. For example, the amount of the alkalizing agent in the pharmaceutical composition provided by the present invention may be set so that the pH of human urine (e.g., early morning urine) becomes pH 6.2 to 6.8 or pH 6.5 to 6.8 when the alkalizing agent is administered to the human. In one embodiment, when a mixture of potassium citrate monohydrate and sodium citrate dihydrate is orally administered to a human as an alkalizing agent, potassium citrate monohydrate and sodium citrate dihydrate may be administered at 0.1 to 5 g / day each for a total of 0.2 to 10 g / day, 0.1 to 3 g / day each for a total of 0.2 to 6 g / day, 0.5 to 3 g / day each for a total of 1 to 6 g / day, preferably 0.5 to 1.5 g / day each for a total of 1 to 3 g / day, 1 to 1.5 g / day each for a total of 2 to 3 g / day, or 0.5 to 1 g / day each for a total of 1 to 2 g / day, and may be administered 1 to 5 times a day, preferably 3 times a day. In one embodiment, when potassium citrate monohydrate or sodium citrate dihydrate is orally administered to a human as an alkalizing agent, 1 to 10 g / day, 1 to 6 g / day, 2 to 5.5 g / day, 1 to 3 g / day, 2 to 3 g / day, or 1 to 1.5 g / day may be administered, and may be administered 1 to 5 times a day, preferably 3 times a day. In one embodiment, when sodium bicarbonate is orally administered to a human as an alkalizing agent, it may be administered at a dose of 1 to 6 g / day, preferably 3 to 5 g / day, in 1 to 5 divided doses per day, preferably 3 times per day. In one embodiment, the alkalinizing agent may be administered chronically, for example, for 1 week or more, 2 weeks or more, 3 weeks or more, 6 weeks or more, 8 weeks or more, 10 weeks or more, 12 weeks or more, 24 weeks or more, 6 weeks or more but not more than 24 weeks, 12 weeks or more but not more than 24 weeks, or 12 weeks or more but not more than 30 weeks. In the above embodiments a) to ssss), examples of kidney disease include acute kidney disease and chronic kidney disease, and examples of chronic kidney disease include chronic kidney disease of stage 3b or less (e.g., stage 2), chronic kidney disease of stage 3b or less (e.g., stage 2) in which the patient's urinary protein excretion is less than 3.5 g / gCr, and chronic kidney disease of stage 3b or more (e.g., stage 4 or more). In one embodiment, the kidney disease patient may be a patient who is treated according to the CKD Medical Care Guide. For example, the kidney disease patient may be a patient who is treated according to the CKD Medical Care Guide with blood pressure management (administration of RA system suppressants such as ARBs and ACE inhibitors, diuretics, and Ca antagonists), proteinuria measures (administration of RA system suppressants), blood glucose level management (administration of α-glucosidase inhibitors), lipid management (administration of statins, fibrates, etc.), anemia management (administration of erythropoietin, etc.), and / or bone and mineral measures (administration of bisphosphonates, etc.).
[0036] 2. Food Composition In one embodiment, the food composition provided by the present invention contains an alkalizing agent, which has the effect of promoting the excretion of uremic substances (e.g., indoxyl sulfate, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid and / or argininosuccinic acid) from the body. The alkalizing agent is as described above in "1. Pharmaceutical Compositions." Examples of the alkalizing agent include a pharma- ceutical acceptable salt of citric acid (e.g., an alkali metal citrate or its hydrate, or a mixture thereof), sodium bicarbonate, and preferably a mixture of potassium citrate monohydrate (C6H5K3O7·H2O) and sodium citrate dihydrate (C6H5Na3O7·2H2O), or sodium citrate dihydrate. The uremic substances are as described above in "1. Pharmaceutical Compositions." Examples of the uremic substances include indoxyl sulfate, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid, and argininosuccinic acid. The content of the alkalizing agent in the food composition provided by the present invention can be appropriately determined depending on the type of food. Examples of the food composition include foods for specified health uses, nutritional supplements, functional foods, foods for hospital patients, and supplements. The food compositions provided by the present invention can be prepared by those skilled in the art depending on the type of food, for example, by blending an alkalizing agent (e.g., potassium citrate and / or sodium citrate) with a food ingredient.
[0037] 3. Methods for determining the decrease in the concentration of uremic substances in the blood In one embodiment, the present invention provides a method for determining a decrease in the concentration of a uremic substance (e.g., indoxyl sulfate, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid and / or argininosuccinic acid) in the blood of a chronic kidney disease patient, comprising measuring the pH of the urine. In one embodiment, the present invention provides a method for determining the promotion of excretion of uremic substances (indoxyl sulfate, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid and / or argininosuccinic acid) into the urine of a patient with chronic kidney disease, the method comprising measuring the pH of the urine. The content of uremic substances (e.g., indoxyl sulfate) in body fluids can be measured by HPLC or enzymatic methods, but these methods require specialized and expensive reagents. As described herein, administration of an alkalizing agent reduces uremic substances in the blood (e.g., indoxyl sulfate concentration, p-cresyl sulfate, phenylacetyl L-glutamine, hippuric acid and / or argininosuccinic acid) and promotes excretion of these uremic substances in the urine. Therefore, by measuring the pH of their urine, patients with chronic kidney disease can very simply and inexpensively determine the reduction in uremic substances in the blood (e.g., indoxyl sulfate concentration, p-cresyl sulfate, phenylacetyl L-glutamine, hippuric acid and / or argininosuccinic acid) and / or the promotion of excretion of uremic substances in the urine (e.g., indoxyl sulfate, p-cresyl sulfate, phenylacetyl L-glutamine, hippuric acid and / or argininosuccinic acid). pH can be measured using well-known techniques, for example, pH test paper, pH test solution, or a simple pH meter. In one embodiment, a chronic kidney disease patient measures the pH of early morning urine (the first urine after waking up) over time from the start of taking an alkalinizing agent (e.g., a mixture of potassium citrate monohydrate and sodium citrate dihydrate, or sodium citrate dihydrate), and if the urine pH increases, it can be simply determined that a decrease in the concentration of uremic substances in the blood (e.g., indoxyl sulfate, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid and / or argininosuccinic acid) and / or promotion of excretion of uremic substances (e.g., indoxyl sulfate, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid and / or argininosuccinic acid) in the urine has been achieved. In one embodiment, a chronic kidney disease patient measures the pH of early morning urine (the first urine after waking up) after taking an alkalinizing agent (e.g., a mixture of potassium citrate monohydrate and sodium citrate dihydrate, or sodium citrate dihydrate), and if the urine pH is in the range of 6.2 to 6.8 (e.g., the urine pH is in the range of 6.5 to 6.8), it can be simply determined that a reduction in the concentration of uremic substances in the blood (e.g., indoxyl sulfate, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid and / or argininosuccinic acid) and / or promotion of excretion of uremic substances (e.g., indoxyl sulfate, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid and / or argininosuccinic acid) into the urine has been achieved. The determination as to whether or not a reduction in the concentration of uremic substances in the blood (e.g., indoxyl sulfate, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid and / or argininosuccinic acid) and / or promotion of excretion of uremic substances in the urine (e.g., indoxyl sulfate, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid and / or argininosuccinic acid) has been achieved in this manner can aid in the diagnosis of whether or not the progression of chronic kidney disease has been inhibited. Thus, in one embodiment, the present invention provides a method for determining inhibition of progression of chronic kidney disease, comprising measuring the pH of urine (e.g., early morning urine) from a patient to whom an alkalinizing agent (e.g., a mixture of potassium citrate monohydrate and sodium citrate dihydrate, or sodium citrate dihydrate) has been administered. If an increase in urinary pH over time or a urinary pH in the range of 6.2 to 6.8 (e.g., a urinary pH in the range of 6.5 to 6.8) is observed, this can aid in the diagnosis that the progression of the disease stage of chronic kidney disease has been inhibited.
[0038] The present invention will be further described below with reference to examples, but the present invention is not limited to these. EXAMPLES
[0039] A human clinical trial was conducted to investigate whether the oral administration of potassium citrate / sodium citrate hydrate and sodium bicarbonate preparations, which are oral alkalinizing agents, promotes urinary excretion of uremic substances.
[0040] 1. Method Patients with chronic kidney disease in stages G2 to G3b (eGFR: 30 to 89 ml / min / 1.73 m 2 Forty-seven patients with chronic kidney disease (CKD, urinary protein excretion less than 3.5 g / gCr) were randomly divided into a potassium citrate / sodium citrate hydrate compound group (Group A: 16 patients), a sodium bicarbonate (sodium bicarbonate) compound group (Group B: 16 patients), and a control group (Group C: 15 patients). Each group received treatment based on the "CKD Medical Care Guide - Summary of Treatment" (hereafter referred to as standard treatment). The control group was not administered any alkalinizing agent. Group A was orally administered three tablets containing 231.5 mg potassium citrate (C6H5K3O7·H2O) and 195.0 mg sodium citrate hydrate (C6H5Na3O7·2H2O) three times a day (morning, noon, evening) for 24 weeks. In cases where the pH of early morning urine was less than 6.5, the dosage was increased to six tablets three times a day (morning, noon, evening) at the discretion of the physician. Group B was orally administered three tablets containing 500 mg sodium bicarbonate three times a day (morning, noon, evening) for 24 weeks. In cases where the pH of early morning urine was less than 6.5, the dosage was increased to six tablets three times a day (morning, noon, evening) at the discretion of the physician. Early morning urine and blood were collected at the start of administration, and 6, 12, and 24 weeks after the start of administration, and each sample was stored at -80°C. Indoxyl sulfate, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid, and argininosuccinic acid in urine and plasma were quantitatively analyzed using the following liquid chromatography triple quadrupole mass spectrometer (LC-MS / MS) with reference to the method used in this field (Sato, E., et. al., Metabolic alteration by indoxyl sulfate in skeletal muscle induce uremic sarcopenia in chronic kidney disease., Sci Rep. 2016 Nov 10;6:36618. doi: 10.1038 / srep36618., etc.). LC was performed using NANOSPACE SI-2 (Shiseido), and CAPCELLPAK MGIII was selected as the analytical column. MS was performed using a TSQ Quantiva (Thermo Fisher Scientific), and five compounds were ionized in negative in-mode and detected using the Selected Reaction Monitoring method. Quantitative values were calculated using a calibration curve prepared using standard solutions of each compound. Statistical analysis was performed using the Mann-Whitney test.
[0041] 2.Results From the results of the LC-MS / MS measurements, the following was calculated for each patient in Group A (group administered a potassium citrate-sodium citrate hydrate formulation), Group B (group administered a sodium bicarbonate formulation), and Group C (control group): (i) Concentration of each uremic substance in plasma at the start of administration (ii) Concentration of each uremic substance in early morning urine at the start of administration (iii) The ratio of the concentration of uremic toxins in early morning urine to the concentration of uremic toxins in plasma at the start of administration (amount of uremic toxins in urine / amount of uremic toxins in plasma) (iv) Plasma concentrations of each uremic toxin 6, 12, and 24 weeks after the start of treatment (v) Concentrations of uremic toxins in early morning urine 6, 12, and 24 weeks after the start of treatment (vi) The ratio of uremic toxin concentration in early morning urine to plasma (amount of uremic toxin in urine / amount of uremic toxin in plasma) at 6, 12, and 24 weeks after the start of administration. (vii) Changes in plasma concentrations of each uremic substance from the start of administration at 6 weeks, 12 weeks, and 24 weeks after the start of administration (viii) Changes in the concentrations of each uremic substance in early morning urine from the start of administration at 6 weeks, 12 weeks, and 24 weeks after the start of administration (ix) Changes from the start of administration in the ratio of uremic toxin concentration in early morning urine to uremic toxin concentration in plasma (amount of uremic toxin in urine / amount of uremic toxin in plasma) at 6, 12, and 24 weeks after the start of administration The mean and SD of each group were calculated for (i) to (ix) above. Note that for each of (iv) to (ix) above, the mean and SD of each group were calculated for all data from 6 weeks, 12 weeks, and 24 weeks after the start of administration in each group. The results are shown in the table below. In the table, Group A, which received the potassium citrate and sodium citrate hydrate formulation, is referred to as "Citrate," and Group B, which received the sodium bicarbonate formulation, is referred to as "Bicarbonate." The numbers in parentheses in the table indicate the number of cases. Table 1-1-1: Indoxyl sulfate content in plasma (μg / mL) Table 1-1-2: Changes in plasma indoxyl sulfate from the start of administration (μg / mL) Table 1-2-1: Amount of indoxyl sulfate in early morning urine (μg / mL) Table 1-2-2: Change in indoxyl sulfate in early morning urine from the start of administration (μg / mL) Table 1-3-1: Ratio of indoxyl sulfate in urine to indoxyl sulfate in plasma. Table 1-3-2: Changes in the ratio of indoxyl sulfate in urine to indoxyl sulfate in plasma from the start of administration. Table 2-1-1: Amount of p-cresyl sulfate in plasma (μg / mL) Table 2-1-2: Changes in plasma p-cresyl sulfate from the start of administration (μg / mL) Table 2-2-1: Amount of p-cresyl sulfate in early morning urine (μg / mL) Table 2-2-2: Change in p-cresyl sulfate in early morning urine from the start of administration (μg / mL) Table 2-3-1: Ratio of p-cresyl sulfate in urine to p-cresyl sulfate in plasma. Table 2-3-2: Changes in the ratio of p-cresyl sulfate in urine to p-cresyl sulfate in plasma from the start of administration. Table 3-1-1: Hippuric acid amount in plasma (μg / mL), Table 3-1-2: Change in plasma hippuric acid from the start of administration (μg / mL) Table 3-2-1: Amount of hippuric acid in early morning urine (μg / mL) Table 3-2-2: Change in hippuric acid in early morning urine from the start of administration (μg / mL) Table 3-3-1: Ratio of hippuric acid in urine to hippuric acid in plasma. Table 3-3-2: Changes in the ratio of hippuric acid in urine to hippuric acid in plasma from the start of administration. Table 4-1-1: Plasma argininosuccinic acid content (μg / mL) Table 4-1-2: Change in plasma argininosuccinic acid from the start of administration (μg / mL) Table 4-2-1: Amount of argininosuccinic acid in early morning urine (μg / mL) Table 4-2-2: Change in argininosuccinic acid in early morning urine from the start of administration (μg / mL) Table 4-3-1: Ratio of argininosuccinic acid in urine to that in plasma. Table 4-3-2: Changes in the ratio of argininosuccinic acid in urine to argininosuccinic acid in plasma from the start of administration. Table 5-1-1: Phenylacetyl-L-glutamine (PAG) content in plasma (μg / mL) Table 5-1-2: Changes in plasma phenylacetyl-L-glutamine (PAG) from the start of administration (μg / mL) Table 5-2-1: Amount of phenylacetyl-L-glutamine (PAG) in early morning urine (μg / mL) Table 5-2-2: Changes in phenylacetyl-L-glutamine (PAG) in early morning urine from the start of administration (μg / mL) Table 5-3-1: Ratio of phenylacetyl-L-glutamine (PAG) amount in urine to that in plasma. Table 5-3-2: Change from the start of administration in the ratio of phenylacetyl-L-glutamine (PAG) amount in urine to phenylacetyl-L-glutamine (PAG) amount in plasma.
[0042] In Group A (administered a citrate: potassium citrate-sodium citrate hydrate compound preparation), the indoxyl sulfate (IS) concentration in early morning urine was increased compared to Group B (administered a bicarbonate: sodium bicarbonate preparation preparation) and Group C (control: control group) (see Tables 1-2-1 and 1-2-2). In Group A, the indoxyl sulfate concentration in plasma was decreased compared to Groups B and C (see Tables 1-1-1 and 1-1-2). The plasma indoxyl sulfate concentration from 6 to 24 weeks was significantly lower in Group A compared to Groups B and C, and the increase in indoxyl sulfate concentration in early morning urine from 6 to 24 weeks was significantly greater in Group A compared to Groups B and C. In addition, administration of a potassium citrate / sodium citrate hydrate combination to patients with chronic kidney disease increased the urinary concentration of indoxyl sulfate, a uremic substance, compared to before administration, and decreased the blood concentration of indoxyl sulfate compared to before administration. Although both are alkaline agents, the potassium citrate / sodium citrate hydrate combination was more effective at lowering blood indoxyl sulfate concentrations and increasing urinary indoxyl sulfate concentrations than sodium bicarbonate preparations. The effect of the potassium citrate / sodium citrate hydrate combination in lowering blood indoxyl sulfate concentrations and increasing urinary indoxyl sulfate concentrations was observed from 12 weeks after administration. The ratio of indoxyl sulfate concentration in urine to indoxyl sulfate concentration in plasma suggests that administration of potassium citrate / sodium citrate hydrate formulation promotes excretion of indoxyl sulfate from blood to urine and promotes excretion from the body. It was also suggested that the excretion effect of indoxyl sulfate from blood to urine is stronger when potassium citrate / sodium citrate hydrate formulation is administered than when sodium bicarbonate formulation is administered (see Tables 1-3-1 and 1-3-2).
[0043] [Table 1-1-1]
[0044] [Table 1-1-2]
[0045] [Table 1-2-1]
[0046] [Table 1-2-2]
[0047] [Table 1-3-1]
[0048] [Table 1-3-2]
[0049] Regarding p-cresyl sulfate (PCS), the p-cresyl sulfate concentration in early morning urine was higher in Group A (Citrate: group administered a potassium citrate and sodium citrate hydrate compound preparation) compared to Group C (Control: control group), and the p-cresyl sulfate concentration in early morning urine was higher in Group A (Citrate: group administered a potassium citrate and sodium citrate hydrate compound preparation) compared to Group B (Bicarbonate: group administered a sodium bicarbonate compound preparation) (see Tables 2-2-1 and 2-2-2). The increase in p-cresyl sulfate concentration in early morning urine from 6 to 24 weeks was significantly greater in Group A compared to Groups B and C. Furthermore, administration of a potassium citrate / sodium citrate hydrate combination to patients with chronic kidney disease increased the urinary concentration of p-cresyl sulfate, a uremic substance, compared to before administration (see Tables 2-2-1 and 2-2-2). Although both are alkaline agents, the potassium citrate / sodium citrate hydrate combination was more effective at increasing urinary p-cresyl sulfate concentrations than sodium bicarbonate preparations. The effect of the potassium citrate / sodium citrate hydrate combination in increasing urinary p-cresyl sulfate concentrations was observed from 12 weeks after administration. The ratio of p-cresyl sulfate concentration in urine to that in plasma suggests that administration of potassium citrate / sodium citrate hydrate formulation promotes excretion of p-cresyl sulfate from blood into urine, promoting its excretion from the body. It also suggests that the excretion effect of p-cresyl sulfate from blood into urine is stronger with administration of potassium citrate / sodium citrate hydrate formulation than with administration of sodium bicarbonate formulation (see Tables 2-3-1 and 2-3-2).
[0050] [Table 2-1-1]
[0051] [Table 2-1-2]
[0052] [Table 2-2-1]
[0053] [Table 2-2-2]
[0054] [Table 2-3-1]
[0055] [Table 2-3-2]
[0056] Regarding hippuric acid (HA), the concentration of hippuric acid in early morning urine was increased in Group A (Citrate: group administered a compound preparation of potassium citrate and sodium citrate hydrate) compared to Group C (Control: control group) (see Tables 3-2-1 and 3-2-2). In addition, administration of a potassium citrate / sodium citrate hydrate preparation to patients with chronic kidney disease increased the urinary concentration of hippuric acid, a uremic substance, compared to before administration (see Tables 3-2-1 and 3-2-2). Although both are alkaline agents, the potassium citrate / sodium citrate hydrate preparation was more effective at increasing urinary hippuric acid concentrations than sodium bicarbonate preparations. The effect of the potassium citrate / sodium citrate hydrate preparation in increasing urinary hippuric acid concentrations was observed from 6 weeks after administration. Administration of a potassium citrate / sodium citrate hydrate preparation to patients with chronic kidney disease reduced the plasma hippuric acid concentration from 24 weeks after administration compared to before administration. This effect was not seen with the administration of a sodium bicarbonate preparation.
[0057] [Table 3-1-1]
[0058] [Table 3-1-2]
[0059] [Table 3-2-1]
[0060] [Table 3-2-2]
[0061] [Table 3-3-1]
[0062] [Table 3-3-2]
[0063] Regarding argininosuccinic acid (ASA), the concentration of argininosuccinic acid in early morning urine was increased in Group A (Citrate: group administered a compound preparation of potassium citrate and sodium citrate hydrate) compared to Group C (Control: control group) (see Tables 4-2-1 and 4-2-2). In addition, administration of a potassium citrate / sodium citrate hydrate compound to patients with chronic kidney disease increased the urinary concentration of argininosuccinic acid, a uremic substance, compared to before administration (see Tables 4-2-1 and 4-2-2). The effect of the potassium citrate / sodium citrate hydrate compound on increasing urinary argininosuccinic acid concentrations was observed from 12 weeks after administration.
[0064] [Table 4-1-1]
[0065] [Table 4-1-2]
[0066] [Table 4-2-1]
[0067] [Table 4-2-2]
[0068] [Table 4-3-1]
[0069] [Table 4-3-2]
[0070] Concerning phenylacetyl-L-glutamine (PAG), group A (administered a citrate: potassium citrate and sodium citrate hydrate preparation group) had lower plasma phenylacetyl-L-glutamine concentrations and higher early morning urine phenylacetyl-L-glutamine concentrations compared to group C (control group), and group A (administered a potassium citrate and sodium citrate hydrate preparation group) had higher early morning urine phenylacetyl-L-glutamine concentrations compared to group B (administered a bicarbonate: sodium bicarbonate preparation group) (see Tables 5-1-1 and 5-2-2). In addition, administration of potassium citrate / sodium citrate hydrate to patients with chronic kidney disease increased the urinary concentration of phenylacetyl-L-glutamine, a uremic substance, compared to before administration (see Tables 5-2-1 and 5-2-2). Although both are alkalizing agents, potassium citrate / sodium citrate hydrate showed a higher effect of increasing urinary phenylacetyl-L-glutamine concentration than sodium bicarbonate preparations. The effect of potassium citrate / sodium citrate hydrate in increasing urinary phenylacetyl-L-glutamine concentration was observed from 12 weeks after administration. Administration of potassium citrate / sodium citrate hydrate to patients with chronic kidney disease reduced the plasma concentration of phenylacetyl-L-glutamine, a uremic substance, compared to before administration (see Tables 5-1-1 and 5-2-2). The ratio of phenylacetyl-L-glutamine concentration in urine to that in plasma suggests that administration of potassium citrate / sodium citrate hydrate formulation promotes excretion of phenylacetyl-L-glutamine from the blood into urine, promoting its excretion from the body. It also suggests that the excretion effect of phenylacetyl-L-glutamine from the blood into urine is stronger with administration of potassium citrate / sodium citrate hydrate formulation compared to administration of sodium bicarbonate formulation (see Tables 5-3-1 and 5-3-2).
[0071] [Table 5-1-1]
[0072] [Table 5-1-2]
[0073] [Table 5-2-1]
[0074] [Table 5-2-2]
[0075] [Table 5-3-1]
[0076] [Table 5-3-2]
[0077] The effects of potassium citrate-sodium citrate hydrate preparations (Citrate) and sodium bicarbonate preparations (Bicarbonate) on the plasma concentration, early morning urine concentration, and ratio of early morning urine concentration to plasma concentration of each uremic substance are summarized in the table below. In the table below, the control drug is the sodium bicarbonate preparation (Citrate) in the case of potassium citrate-sodium citrate hydrate preparations (Citrate), and the potassium citrate-sodium citrate hydrate preparation (Citrate) in the case of sodium bicarbonate preparations (Bicarbonate). When the effect is significantly superior to the control group or the control drug group, a circle is recorded, when the effect is significantly inferior to the control group or the control drug group, a cross is recorded, and when there is no significant difference, a - is recorded. Note that the effect of the sodium bicarbonate preparation (Bicarbonate) group on the indoxyl sulfate concentration in early morning urine compared to the control group is recorded as (○) in the table below. This is because the sodium bicarbonate preparation (bicarbonate)-administered group had a significantly increased indoxyl sulfate concentration in early morning urine compared to the control group, but the indoxyl sulfate concentration in early morning urine after administration of the sodium bicarbonate preparation (bicarbonate) decreased compared to when administration began, so it is not possible to determine whether there is an effect of promoting the excretion of indoxyl sulfate in the urine.
[0078] [Table 6]
[0079] From the above table, it can be seen that, in general, potassium citrate-sodium citrate hydrate preparations have a higher effect on excreting uremic substances from the body compared to sodium bicarbonate preparations. It was also suggested that administering an alkalizing agent to chronic kidney disease patients in stage G2 as well as stage G3b can inhibit the progression of chronic kidney disease, and that potassium citrate-sodium citrate hydrate preparations inhibit the progression of chronic kidney disease more than sodium bicarbonate preparations.
Claims
1. A pharmaceutical composition for treating or preventing cardiovascular diseases associated with chronic kidney disease and for reducing the concentration of uremic substances in the blood, comprising an alkalizing agent, wherein the alkalizing agent is a mixture of sodium citrate or a hydrate thereof and potassium citrate or a hydrate thereof.
2. A pharmaceutical composition for treating or preventing cardiovascular disease associated with chronic kidney disease and for increasing the concentration of uremic substances in urine, comprising an alkalizing agent, wherein the alkalizing agent is a mixture of sodium citrate or a hydrate thereof and potassium citrate or a hydrate thereof.
3. The pharmaceutical composition described in claim 1 or 2, further for improving arteriosclerosis.
4. A pharmaceutical composition for inhibiting the progression of chronic kidney disease and for reducing the concentration of uremic substances in the blood, comprising an alkalizing agent, wherein the alkalizing agent is a mixture of sodium citrate or a hydrate thereof and potassium citrate or a hydrate thereof.
5. A pharmaceutical composition for inhibiting the progression of chronic kidney disease and for increasing the concentration of uremic substances in urine, comprising an alkalizing agent, wherein the alkalizing agent is a mixture of sodium citrate or a hydrate thereof and potassium citrate or a hydrate thereof.
6. A pharmaceutical composition for inhibiting the progression from acute kidney disease to chronic kidney disease and for reducing the concentration of uremic substances in the blood, comprising an alkalizing agent, wherein the alkalizing agent is a mixture of sodium citrate or a hydrate thereof and potassium citrate or a hydrate thereof.
7. A pharmaceutical composition for inhibiting the progression of acute kidney disease to chronic kidney disease and for increasing the concentration of uremic substances in urine, comprising an alkalizing agent, wherein the alkalizing agent is a mixture of sodium citrate or a hydrate thereof and potassium citrate or a hydrate thereof.
8. A pharmaceutical composition described in any one of claims 1 to 7, administered to patients with early stage chronic kidney disease.
9. A pharmaceutical composition described in any one of claims 1 to 8, administered to patients with chronic renal failure at stage G3b or below.
10. A pharmaceutical composition described in any one of claims 1 to 9, administered to a patient with stage G2 chronic renal failure.
11. A pharmaceutical composition described in any one of claims 1 to 10, wherein the alkalinizing agent is designed to be administered in an amount that improves acidic urine in gout or hyperuricemia.
12. A pharmaceutical composition described in any one of claims 1 to 11, wherein administration of the alkalinizing agent increases the concentration of uremic substances in the urine compared to before administration.
13. The pharmaceutical composition of any one of claims 1 to 12, wherein the pharmaceutical composition is a tablet.
Citation Information
Patent Citations
Method of measuring indoxylsulfuric acid
JP2016191707A
Method or apparatus for determination of severity of renal diseases and method for operation of the apparatus
WO2010126146A1
Cited By
Blood purification through alkalifying agent
JP2024133407A
